GlobeNewswire by notified

CARBIOS and Hündgen enter supply agreement for world’s first PET biorecycling plant

Share

CARBIOS and Hündgen enter supply agreement for world’s first PET biorecycling plant

  • From end 2026, Hündgen will supply 15kt/year of post-consumer PET flakes to CARBIOS’ first commercial plant

Clermont-Ferrand, France, Thursday 2 May 2024 (06.45am CEST) CARBIOS (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, and Hündgen Entsorgungs GmbH & Co. KG (Hündgen), a waste management expert in logistics, sorting services and the recycling of recyclable materials from waste mixtures, announce the signing of a non-binding Memorandum of Understanding relating to the sourcing, preparation and recycling of 15kt/year of post-consumer PET waste using CARBIOS’ biorecycling technology at its first commercial plant in Longlaville, from end 2026.

The partnership will leverage Hündgen’s expertise and network in the sourcing and preparation of light packaging waste collected from German households. This PET waste will be prepared into flakes ready for biorecycling using CARBIOS’ enzymatic depolymerization technology, which produces food-grade PTA and MEG, further re-polymerized into PET.

The supply partnership with Hündgen contributes to securing the majority of CARBIOS’ feedstock needs for its first commercial plant in Longlaville, France. This plant will have a 50kt/year capacity when it will be fully operational and is currently under construction. This latest sourcing announcement comes in addition to previously announced agreements, such as with Landbell Group for food trays from Germany, and the winning CITEO tender for trays in France. The location of the Longlaville plant is strategically close to nearby waste supplies in Belgium, Germany and Luxembourg.

Through its enzymatic depolymerization process, CARBIOS can process all types of PET waste, including waste that cannot be recycled with current technologies. Multilayered, colored, and opaque packaging waste as well as polyester textile waste now have circular recycling solutions.

Emmanuel Ladent, CEO of CARBIOS:“Through our partnership with Hündgen, CARBIOS has now secured most of the feedstock supply for our first commercial plant. CARBIOS’ innovative biorecycling technology enables the conversion of diverse PET waste allowing more flexibility in sourcing, and price-competitiveness compared with high-demand clear bottles. Our local sourcing strategy has also paid off and demonstrates the importance of locating biorecycling plants near waste supplies, an expertise that we’re keen to share with our future license holders.”

Christian Hündgen, CEO of Hündgen Entsorgungs GmbH & Co.KG:“Establishing new standards in the field of plastic packaging recycling requires the development and implementation of innovative technologies and the promotion of cross-border cooperation. In this context, we are delighted to be part of one of the leading projects in Europe in the field of PET non-bottle recycling.”

###

About CARBIOS:

CARBIOS is a biotech company developing and industrializing biological solutions to reinvent the life cycle of plastic and textiles.  Inspired by nature, CARBIOS develops enzyme-based processes to break down plastic with a mission to avoid plastic and textile pollution, and accelerate the transition to a circular economy. Its two disruptive technologies for the biorecycling of PET and the biodegradation of PLA are reaching industrial and commercial scale.  Its biorecycling demonstration plant has been operational since 2021 and a first industrial plant, in partnership with Indorama Ventures, is currently under construction.  CARBIOS, founded in 2011 by Truffle Capital, has received scientific recognition, notably with the cover of Nature, and is supported by prestigious brands in the cosmetics, Food & Beverage and apparel industries to enhance their products’ recyclability and circularity. Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe are members of a packaging consortium founded by CARBIOS and L’Oréal. On, Patagonia, PUMA, PVH Corp. and Salomon collaborate with CARBIOS in a textile consortium.

Visit www.carbios.com/en to find out more about biotechnology powering plastic and textile circularity.

For latest news and media assets, visit our newsroom: www.carbios.com/newsroom/en/

LinkedIn: CARBIOS / Instagram: insidecarbios

Information on CARBIOS shares:

ISIN Code:FR0011648716
Ticker Code:Euronext Growth: ALCRB
LEI:969500M2RCIWO4NO5F08

CARBIOS is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in CARBIOS in any country.


About Hündgen Entsorgungs GmbH & Co. KG

As a modern structured family business, Hündgen Entsorgungs GmbH & Co. KG offers a maximum of entrepreneurial flexibility. Adjustments to changing ecological or economic conditions can be implemented directly. On the one hand, this guarantees a high ecological standard in terms of environmental protection. On the other hand, a good customer service can be guaranteed in the sense of the entrepreneurial objectives by targeted personal approach and consultation in all disposal questions.

Thus, in addition to the transport of waste, recyclable materials and mixtures of recyclable materials, their sorting and also the marketing and utilization of secondary raw materials in international trade are among the fields of activity of Hündgen Entsorgungs GmbH & Co. KG. Planning and development of innovative disposal and recycling concepts for trade and industry as well as consulting and cooperation with national and international institutes and local authorities complete the wide range of services. 

www.huendgen-entsorgung.de | LinkedIn | Facebook


For additional information, please contact:

CARBIOSRelations Presse
(France)
Relations Presse
(U.S)
Relations Presse
(DACH & UK)
Melissa FlauraudIconicRooney PartnersMC Services
Relations PresseAurélie AKNIN / Clémence NAIZETKate L. BarretteAnne-Hennecke
melissa.flauraud@carbios.comcarbios@iconic.frkbarrette@rooneyco.comcarbios@mc-services.eu
+33 (0)6 30 26 50 04+33 (0)6 68 28 21 78+1 212 223 0561+49 (0)211 529 252 22
Benjamin Audebert
Relations Investisseurs
contact@carbios.com
+33 (0)4 73 86 51 76
HÜNDGEN ENTSORGUNGS GmbH & Co. KG
Marc Schönn
Relations Presse
m.schoenn@huendgen-entsorgung.de
+49 (0) 2255 9430 60


Disclaimer on forward-looking statements and risk factors:

This press release contains forward-looking statements, not historical data, and should not be construed as a guarantee that the facts and data stated will occur. These forward-looking statements are based on data, assumptions and estimates considered reasonable by CARBIOS. CARBIOS operates in a competitive and rapidly evolving environment. It is therefore not in a position to anticipate all risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of a risk or combination of risks could lead to results that differ significantly from those mentioned in any forward-looking statement. CARBIOS draws your attention to the fact that forward-looking statements are in no way a guarantee of its future performance and that its actual financial position, results and cash flows and the development of the sector in which CARBIOS operates may differ significantly from those proposed or suggested by the forward-looking statements contained in this document. In addition, even if CARBIOS’ financial position, results, cash flows and developments in the industry in which it operates are consistent with the forward-looking information contained in this document, such results or developments may not be a reliable indication of CARBIOS’ future results or developments. Readers are advised to carefully consider the risk factors described in the Universal registration document filed with the French Market Authority (“AMF”), as well as in the half-year financial report available free of charge on the Company’s website. Should all or any part of these risk factors materialize or others, in no case whatsoever will CARBIOS be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages. This information is given only as of the date of this press release. CARBIOS makes no commitment to publish updates to this information or on the assumptions on which it is based, except in accordance with any legal or regulatory obligation applicable to it.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Constellation Brands to Present at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 202416.5.2024 22:30:20 CEST | Press release

VICTOR, N.Y., May 16, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 2024 in New York, NY. The presentation is scheduled to begin at 2:30 p.m. EDT and is expected to cover the company’s strategic business initiatives, financial metrics, and operating performance, as well as outlook for the future. A live, listen-only webcast of the presentation will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the presentation begins, financial information discussed in the presentation, and a reconciliation of reported GAAP financial measures with comparable and other non-GAAP financial measures, will also be available

DBV Technologies Announces Results of its 2024 Combined General Meeting16.5.2024 22:30:00 CEST | Press release

Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by the Board of Directors. These resolutions and their results are posted on the Investors/Annual General Meetings section of the Company’s website: https://dbv-technologies.com/events/2024-annual-general-meeting/. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with sign

Clean Motion AB delårsredogörelse för januari-mars 202416.5.2024 22:10:00 CEST | Pressemelding

Elfordonstillverkaren Clean Motion AB presenterar sin delårsrapport för januari-mars 2024. Bolaget redovisar en försäljning på 38 (45) TSEK och ett rörelseresultat exklusive avskrivningar (EBITDA) på -2 949 (-1 825) TSEK. Bolaget meddelar även att ett licensavtal är tecknat för tillverkning av Zbee i Indien samt att deras nya produktionslokal för EVIG i Jonsered nu är godkänd. Sofia Haby, VD kommenterar; ”Vi har jobbat intensivt under kvartalet med både typgodkännande-processen och flytt till nya lokaler. Kvartalet har präglats av de förseningar som vi drabbats av med vårt typgodkännande, vilket förhindrat försäljning i Europa. Jag kan nu med glädje meddela att det mest kritiska testet blev godkänt igår kväll! Under de senaste månaderna har vi jobbat med att färdigställa vår nya produktionslokal i Jonsered. Jag är övertygad om att vi genom att samla alla resurser under ett tak, kommer att åstadkomma stora effektivitetsförbättringar. Teamet har arbetat dedikerat med att säkerställa en s

Galapagos creates new subscription right plans16.5.2024 22:01:00 CEST | Press release

Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 16 May 2024, the Board of Directors of Galapagos approved “Subscription Right Plan 2024 BE”, intended for members of personnel of the company, “Subscription Right Plan 2024 RMV,” intended for the employees of its French subsidiary, Galapagos SASU, and “Subscription Right Plan 2024 ROW”, primarily intended for the employees of its other non-Belgian subsidiaries, within the framework of the authorized capital. Under these subscription right plans, 1,614,000 subscription rights were created, subject to acceptances, and offered to the beneficiaries of the plans. The subscription rights have an exercise term of eight years as of the date of the offer and have an exercise price of €

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH16.5.2024 22:00:00 CEST | Press release

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, has been without clinical symptoms throughout the period of observation and has fully recovered.The DMC review confirms the good safety profile of lanifibranor. Daix (France), Long Island City (New York, United States), May 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepa

HiddenA line styled icon from Orion Icon Library.Eye